Nektar Therapeutics
NKTR
Rank in Stocks
#8333
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global... Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
Share Price
$37.83
Last synced: 2026-11-09
Market Cap
$1.09B
Change (1 day)
1.52%
Change (1 year)
-36.17%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Nektar Therapeutics (NKTR)
Category
Healthcare
Operating Margin for Nektar Therapeutics (NKTR)
Operating Margin as of November 2026 TTM: -240.38%
According to Nektar Therapeutics's latest financial reports, its current operating margin (TTM) is -240.38%. At the end of 2025 the company had an operating margin of -236.77%.
Operating Margin history for Nektar Therapeutics from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -240.38% | 1.52% |
| 2025 | -236.77% | 121.53% |
| 2024 | -106.88% | -29.91% |
| 2023 | -152.49% | -41.57% |
| 2022 | -260.97% | -40.39% |
| 2021 | -437.76% | 76.20% |
| 2020 | -248.45% | -35.29% |
| 2019 | -383.92% | -765.95% |
| 2018 | 57.65% | -397.47% |
| 2017 | -19.38% | -71.59% |
| 2016 | -68.22% | 435.90% |
| 2015 | -12.73% | 55.05% |
| 2014 | -8.21% | -89.82% |
| 2013 | -80.67% | -53.61% |
| 2012 | -173.91% | 0.30% |
| 2011 | -173.39% | 875.75% |
| 2010 | -17.77% | -86.56% |
| 2009 | -132.25% | 44.30% |
| 2008 | -91.65% | 592.22% |
| 2007 | -13.24% | -81.90% |
| 2006 | -73.14% | -49.43% |
| 2005 | -144.63% | 123.50% |
| 2004 | -64.71% | 3.89% |
| 2003 | -62.29% | -40.97% |
| 2002 | -105.52% | -68.19% |
| 2001 | -331.70% | 158.94% |
| 2000 | -128.10% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.16% |
US
|
|
| -149.01% | -99.38% |
US
|
|
| 25.57% | -100.11% |
AU
|
|
| 31.23% | -100.13% |
BE
|
|
| 29.35% | -100.12% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Nektar Therapeutics's operating margin
What is Nektar Therapeutics's operating margin?
Nektar Therapeutics's operating margin is -240.38%, as of Nov 2026.
What was Nektar Therapeutics's operating margin in 2025?
In 2025, Nektar Therapeutics's operating margin was -236.77%, compared with -106.88% in 2024.
How has Nektar Therapeutics's operating margin changed since 2020?
From 2020 to 2025, Nektar Therapeutics's operating margin was highest in 2024 (-106.88%) and lowest in 2021 (-437.76%).
How does Nektar Therapeutics's operating margin compare with similar companies?
Nektar Therapeutics's operating margin (-240.38%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.